Rhumbline Advisers Sells 25,227 Shares of IQVIA Holdings Inc. $IQV

Rhumbline Advisers decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 441,015 shares of the medical research company’s stock after selling 25,227 shares during the quarter. Rhumbline Advisers owned approximately 0.26% of IQVIA worth $83,766,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. increased its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. grew its position in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA during the third quarter valued at approximately $36,000. Asset Dedication LLC raised its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares in the last quarter. Finally, Rothschild Investment LLC lifted its stake in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $168.78 on Friday. The company has a 50 day simple moving average of $224.30 and a two-hundred day simple moving average of $209.18. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a market capitalization of $28.74 billion, a price-to-earnings ratio of 21.47, a P/E/G ratio of 1.71 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same period in the previous year, the firm posted $3.12 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Jefferies Financial Group dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Morgan Stanley set a $240.00 price objective on shares of IQVIA in a report on Wednesday. UBS Group reduced their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. TD Cowen increased their target price on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $238.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.